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Abstract
Background: The potential benefits of long-acting injectable chemoprotection (LAI-C) against malaria
have been recently recognized, prompting a call for suitable candidate drugs to help meet this need. On
the basis of its known pharmacodynamic and pharmacokinetic profiles after oral dosing, ELQ-331, a
prodrug of the parasite mitochondrial electron transport inhibitor ELQ-300, was selected for study of
pharmacokinetics and efficacy as LAI-C in mice.
Methods: Four trials were conducted in which mice were injected with a single intramuscular dose of
ELQ-331 or other ELQ-300 prodrugs in sesame oil with 1.2% benzyl alcohol; the ELQ-300 content of the
doses ranged from 2.5 to 30 mg/kg. Initial blood stage challenges with Plasmodium yoelii were used to
establish the model, but the definitive study measure of efficacy was outcome after sporozoite
challenge with a luciferase-expressing P.yoelii, assessed by whole-body live animal imaging. Snapshot
determinations of plasma ELQ-300 concentration ([ELQ-300]) were made after all prodrug injections;
after the highest dose of ELQ-331 (equivalent to 30 mg/kg ELQ-300), both [ELQ-331] and [ELQ-300] were
measured at a series of timepoints from 6 hours to 5 ½ months after injection.
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Results: A single intramuscular injection of ELQ-331 outperformed four other ELQ-300 prodrugs and, at
a dose equivalent to 30 mg/kg ELQ-300, protected mice against challenge with P. yoelii sporozoites for
at least 4 ½ months. Pharmacokinetic evaluation revealed rapid and essentially complete conversion of
ELQ-331 to ELQ-300, a rapidly achieved (< 6 hours) and sustained (4-5 months) effective plasma ELQ-300
concentration, maximum ELQ-300 concentrations far below the estimated threshold for toxicity, and a
distinctive ELQ-300 concentration vs. time profile. Pharmacokinetic modeling indicates a high-capacity,
slow-exchange tissue compartment which serves to accumulate and then slowly redistribute ELQ-300
into blood, and this property facilitates an extremely long period during which ELQ-300 concentration is
sustained above a minimum fully-protective threshold (60-80 nM).
Conclusions: Extrapolation of these results to humans clearly predicts that ELQ-331 should be capable of
meeting and far-exceeding currently published duration-of-effect goals for antimalarial LAI-C. Allometric
scaling from mice to humans would predict a several-fold enhancement in the relationship between
duration-of-effect and dose, and available drug engineering and formulation technologies would be
expected to offer significant improvement over the simple powder in sesame oil used here.
Furthermore, the distinctive pharmacokinetic profile of ELQ-300 after treatment with ELQ-331 may
facilitate durable protection using a variety of delivery and formulation options, and may enable
protection for far longer than 3 months. Particularly in light of the favorable pharmacodynamic profile of
ELQ-300, ELQ-331 warrants consideration as a leading prototype for LAI-C.
Background
Despite a remarkable recent reduction in the global burden of malaria, there remains an urgent need for
novel antimalarial drug treatments. It is evident that new drugs are needed to maintain efficacy in the
face of emerging drug resistance, but even in the absence of drug resistance there are settings and subpopulations in which drugs are unavailable, unaffordable, impractical, ineffective, or unsafe. These
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concerns clearly apply to current prevention and treatment applications and are only magnified when
future eradication efforts are also considered. For some needs, many antimalarial drug options exist, for
others only a few, and for some none at all. For this reason, thought-leaders in the field have sought to
identify critical gaps in antimalarial drug options, to define the ideal characteristics of drugs to fill each
gap, and to disseminate that information in the form of Target Product Profiles (TPPs) (1).
Until recently, TPPs have focused on maintaining or improving the effectiveness of drugs for
conventional uses: treatment of malaria, prophylaxis in the non-immune facing new malaria exposure,
and intermittent prophylaxis in critical sub-groups among populations with endemic exposure. Missing
from this list has been any role for drugs to achieve sustained, large scale malaria prevention among
populations in endemic regions. It has been long-hoped that a vaccine could provide the effective and
durable protection needed for that purpose, and long-assumed that drug treatment could not feasibly
achieve it. The importance and the urgency of finding options to provide effective and durable
protection has increased as strategies to eradicate malaria have been considered. Whether by
protecting the whole population early in the process, or more likely by targeting critical groups late in
the process, it is evident that sustained, reliable protection against infection and transmission will be an
absolute requirement for future successful eradication efforts.
The results of vaccine studies to-date indicate that a feasible, highly-effective, and durably-protective
vaccine will not be available soon (2). At the same time, an increasing body of information has
demonstrated the safety and efficacy of long-acting injectable (LAI) medications to treat other
conditions (3-6), and pilot studies have shown durable protection against malaria in mice after
intramuscular (IM) drug injection (7, 8). Together, these observations prompted the Medicines for
Malaria Venture (MMV) to develop the first drug TPP for long-acting injectable chemoprotection (LAI-C)
against malaria (9).
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As a starting point, the MMV suggested the following priorities for LAI-C candidates: (1) Multi-stage
activity including liver and blood stage schizonticidal, and transmission-blocking efficacy, (2) rapid-onset
high efficacy, sustained for 3 months, (3) minimal or no consequential drug-drug interactions, (4) high
safety and tolerability both at the injection site and systemically, including in pediatric patients and
those with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, and (5) formulations with suitable
viscosity (injectable through small-bore needles), shelf-life (>2-3 years in tropical conditions), and low
cost. The history of drug resistance development during blood stage infection has led to the
recommendation that two drugs with the above features be combined for LAI-C, but it is acknowledged
that a single drug might prove adequate, given the likely diminished risk of de novo drug resistance
during causal prophylaxis. Because drugs used for LAI-C will be present at the injection site, in blood,
and in tissues for a very long time period, safety testing will be more complex, lengthy, and costly than
that for other drug applications. Since any prior toxicology information will therefore be essential to
down-select appropriate drugs for LAI-C, the MMV has suggested dividing candidates for LAI-C into
three conceptual groups: tier 1, comprised of existing pharmaceuticals with available clinical safety
information; tier 2, new drugs which can be delivered orally for initial safety testing; and tier 3, drugs
that can only be tested parenterally because adequate oral delivery is not possible.
Very few antimalarials provide causal prophylactic efficacy, so tier 1 candidates include only
atovaquone, with or without proguanil; the anti-folates, sulfadoxine and pyrimethamine; and the 8aminoquinolines, primaquine and tafenoquine. While each has attractive features, each has liabilities.
Atovaquone has a remarkable propensity to rapidly generate high-grade resistance (10), although that
risk is likely less during causal prophylaxis and may be further mitigated by the diminished
transmissibility of highly atovaquone-resistant parasites (11). To match a partner drug and provide
effective coverage for three months, the relatively short elimination half-life of proguanil (12) would
mandate a very large delivered dose and attendant possible toxicity risk, or extensive formulation
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engineering to control release from the injection site. The antifolates face widespread, pre-existing drug
resistance (13), and although antifolate-caused life-threatening dermatologic toxicity (e.g., StevensJohnson syndrome) is uncommon (14), the risk likely precludes consideration of these drugs for LAI-C.
Although recent studies indicate the safety and efficacy of some 8-aminoquinoline dosages in some
patients with G-6-PD deficiency (15), LAI-C would result in months of continuous oxidative stress making
it almost certain that G-6-PD testing would be required prior to use, and likely that G-6-PD deficiency
would be a contraindication for 8-aminoquinoline LAI-C. Furthermore, 8-aminoquinolines could be
ineffective in the small but significant proportion of the population lacking adequate CYP 2D6 to form
active metabolites (16). From among these tier 1 candidates, atovaquone may be the most promising,
but no single drug or two-drug combination appears likely to provide sufficiently feasible, effective, and
safe LAI-C in the context of eradication efforts in regions of high endemicity.
ELQ-300 (see Table 1) is an experimental antimalarial with causal prophylactic, blood stage
schizonticidal, and transmission-blocking activity (17). It acts at the Qi site of cytochrome bc1 to
selectively inhibit parasite mitochondrial electron transport and inter-related pyrimidine biosynthesis
(17, 18), thus preventing nucleic acid synthesis. ELQ-300 has low nanomolar efficacy in vitro against
Table 1 title: Structures of ELQ-300, ELQ-331, and other ELQ-300 prodrugs included in this report
Compound ID

Structure

ELQ-300

ELQ-331
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ELQ-494

ELQ-495

ELQ-499

ELQ-500

Table 1 legend : The synthesis, chemical analysis, physicochemical properties, and other details related
to ELQ-300 and ELQ-331 are previously published (17, 19). ELQ-494, ELQ-495, ELQ-499, and ELQ-500 will
be described as part of a future report covering the entire scope of the ELQ-300 prodrug project.
blood stage Plasmodium falciparum, vivax (17), and knowlesi (personal communication, D.A. van
Schalkwyk) including multidrug-resistant laboratory strains and clinical isolates, and distinctly notable
transmission-blocking potency (20). Compared to atovaquone, which acts at the Qo site of cytochrome b
and rapidly gives rise to drug resistance in vitro, the propensity to develop ELQ-300 resistance is far
lower (>10-5 for atovaquone, <10-8 for ELQ-300) (17, 21). Inhibition of cytochrome bc1 electron transport
by ELQ-300 is also far more parasite-specific (IC50 P. falciparum = 0.56 nM, IC50 human = >10,000 nM)
when compared to atovaquone (IC50 P. falciparum = 2 nM, IC50 human = 460 nM) (17). In extensive preclinical testing, ELQ-300 has an excellent safety profile, no evident in vitro drug-drug interactions, and
slow elimination which facilitates single-dose cures in mice. Oral bioavailability is adequate to prove
efficacy and to evaluate pharmacokinetics (PK) in animals, but the poor aqueous solubility and high
crystallinity of ELQ-300 limits the extent and predictability of exposure after oral dosing, making it
unsuitable as an orally-delivered drug, despite its other favorable features.
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To improve oral bioavailability while preserving the highly desirable features of ELQ-300, we have
sought to develop prodrugs of ELQ-300 that are better absorbed from the gastrointestinal tract but then
are rapidly converted to ELQ-300 (19, 22). ELQ-331 (see Table 1), an alkoxycarbonate ester of ELQ-300,
has emerged as a leading contender. ELQ-331 also has limited aqueous solubility, but with far less
tendency to form insoluble crystals and, probably on that basis, results in much-increased ELQ-300
exposure after oral dosing. In mice, the in vivo efficacy of ELQ-331 by gavage is superior to ELQ-300 (19),
and in rats, 10 mg/kg of an ELQ-331 formulation resulted in a mean maximum plasma [ELQ-300] of 12.6
µM (manuscript submitted). ELQ-331 has undergone successful efficacy testing against blood stage
infection and sporozoite challenge in mice (19), and toxicology assessment rats (see Additional File 1);
and we continue to advance ELQ-331 and other prodrugs for oral use. It is evident, however, that the
pharmacodynamic and PK features of ELQ-331 are ideal for a LAI-C candidate, and that physicochemical
features which are problematic for oral dosing might be beneficial for its use as a LAI-C. We therefore
undertook the following studies in mice to assess the efficacy and PK profile of IM ELQ-331 in sesame
oil, and to conduct a limited comparison with other ELQ-300 prodrugs.
Methods
ELQ-300 prodrug treatment in mice: All treatments were administered in 0.05 mL of sesame oil
containing 1.2% benzyl alcohol (v/v), injected through a 0.625-inch, 25 gauge needle into the caudal
thigh of mice weighing 25-35 gm. To facilitate comparisons, prodrug doses were calculated and are
expressed on the basis of ELQ-300 content. For example, mice in “10 mg/kg” ELQ-331 treatment groups
received 12.1 mg/kg of ELQ-331, the molar equivalent of 10 mg/kg of ELQ-300. Stable solubility of each
prodrug in the injection vehicle was determined prior to dosing (see Additional File 2).
Blood stage challenges to assess activity against blood stage infection: Blood stage challenges were
done using a lethal P. yoeliiK parasite (subsp. yoelii, Strain K (Kenya), BEI Resources, NIAID, NIH: MRA-
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428, contributed by Wallace Peters and Brian L. Robinson). Mice were injected intravenously via tail vein
with 3 X 105 P. yoeliiK-infected erythrocytes and evaluated by microscopy of Giemsa-stained blood
smears 5 days later. Mice that remained parasite-free were reassessed by blood smears weekly for at
least 28 days, at which time they were scored as “not infected”. Mice with any evident parasitemia at
any time point during the study were scored as “infected” and euthanized.
Sporozoite challenges to assess causal prophylactic activity: Sporozoite challenges were done using a
transgenic, non-lethal P. yoelii XNL parasite that constitutively expresses a GFP-luciferase fusion protein
throughout the life cycle (Py-GFP-luc) (23). Female six to eight-week-old Swiss Webster (SW) mice were
injected with Py-GFP-luc-infected blood to begin the growth cycle. The infected mice were used to feed
female Anopheles stephensi mosquitoes after gametocyte exflagellation was observed. Ten days after
the blood meal, 15–20 mosquitoes were dissected to evaluate midgut oocyst formation. At day 14 or 15
post-blood meal, salivary glands were removed, sporozoites liberated using a pestle and then isolated by
centrifugation through glass wool. Sporozoites were then counted by hemocytometer and diluted with
incomplete RPMI to a concentration of 5 X 105 per mL. Samples were maintained on ice from the time of
salivary gland dissection until final dilution in RPMI. Mice were then injected with 0.2 mL (105
sporozoites) intravenously via tail vein and evaluated by whole-animal bioluminescence imaging 2 days
after inoculation to assess liver infection, and 5-6 days after inoculation to determine if blood stage
infection occurred.
Whole-animal imaging was done using the IVIS Spectrum CT and Living Image software (Perkin-Elmer).
Mice were injected intraperitoneally with 150 mg/kg D-luciferin (XenoLight, Perkin-Elmer) in PBS, 10
minutes prior to imaging, then shortly before and throughout imaging, anesthesia was induced and
maintained with isoflurane. If no luminescence signal was evident using auto exposure settings,
exposure time was increased in stepwise fashion to at least 2 minutes at widest aperture. Optimal
settings often varied between imaging sessions, but for all groups of mice compared head-to-head at
9
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any given time point, all camera and software settings were identical. Image assessment was qualitative
only, to determine the presence or absence of evident infection.
Blood sampling and processing for determination of plasma ELQ-331 and ELQ-300 concentration: Mice
were warmed for 5-10 minutes under a lamp prior to sampling. A fifty microliters blood sample was
collected from a tail vein using a calibrated, heparinized microcapillary tube, and transferred to a
microfuge tube containing 5.7 µL of 500 mM sodium fluoride, maintained in an ice bath before and after
sampling. This protocol had been previously shown by us to limit ex vivo esterase metabolism of ELQ331 to <2% (see Additional File 2). At each time point, after all required mice were sampled, the
specimens were moved to a cold room, centrifuged at high speed for 1 minute and then 20 µL of
supernatant plasma was transferred to a new tube, which was immediately frozen at -80° C until
analysis.
Analytical methods for determination of plasma ELQ-331 and ELQ-300 concentration: Prodrug and drug
concentrations were analyzed using an Applied Biosystems QTRAP 4000 (Foster City, CA) with
electrospray ionization in positive mode. The mass spectrometer was interfaced to a Shimadzu
(Columbia, MD) SIL-20AC XR auto-sampler followed by two LC-20AD XR LC pumps. The instrument was
operated with the following settings: source voltage 5500 kV, GS1 20, GS2 50, CUR 15, TEM 600, and
CAD MEDIUM. The scheduled Multiple Reaction Monitoring (MRM) transitions monitored are listed in
the table below; the bold are used for quantification. Compounds were individually infused and
instrument parameters optimized for each MRM transition. A gradient mobile phase was delivered at a
flow rate of 0.3 mL/min; it consisted of two solvents: A - 0.1% formic acid in water and B - 0.1% formic
acid in acetonitrile. Separation was achieved using a Dacapo DX-C18 column at 40°C and the
autosampler was kept at 30°C to prevent the precipitation of ELQ and related compounds. The gradient
elution was as follows: 40% B, held for 0.5 min; increase to 95% B at 3 min; 100% B was held for 2.5 min;
decrease to 40% B over 0.1 min; hold at 10% B for 1.4 minutes to re-equilibrate. Method modification
10
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was necessary to separate ELQ-331 from the ELQ-300 as there was in-source fragmentation which
initially gave erroneous values for ELQ-300 in the presence of ELQ-331. The retention times were 3.09
minutes for ELQ-300, 2.91 minutes for ELQ-316 (internal standard for ELQ studies [IS]) and 2.98 minutes
for ELQ-331; separate curves were prepared routinely for ELQ-300 and ELQ-331. Data were acquired
using Analyst 1.5.1 software and analyzed using Multiquant 3.0.2.
RetentionTime

Q1

Q3

(min)

Mass

Mass

ELQ-300

3.09

476

ELQ-300

3.09

Compound

DP

EP

CE

CXP

433.1

166

10

61

12

476

426.1

166

10

61

12

2.91

460

417.1

176

10

59

12

2.91

460

239.1

176

10

83

16

ELQ-331

2.98

578

476

100

10

45

14

ELQ-331

2.98

578

433.1

100

10

73

12

ELQ-316
(IS)
ELQ-316
(IS)

Plasma samples were quickly thawed at room temperature and crashed with freshly prepared 1:9
dimethylformamide:acetonitrile with 100 ng/mL ELQ-316 internal standard at a ratio of 5 µL plasma to
95 µL of crash solution. Samples were vortexed for 2 minutes on a pulsing vortexer, centrifuged for 2
minutes at high speed, and the supernatant transferred to sample vials. Prior to analysis the samples
were pre-heated in the autosampler for a minimum of 45 minutes to ensure stable signal. A standard
curve was prepared by spiking commercial mouse plasma with analyte in a range from 1 ng/mL to 2000
ng/mL, crashed and processed identically to test samples.
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Pharmacokinetic analysis: Group statistics (mean ± SEM) for plasma drug concentration values and
graphical representation of concentration vs. time curves were done using Prism 7 software (GraphPad,
San Diego). The apparent maximum concentration (Cmax) and the time from dosing to Cmax (Tmax) were
determined by inspection of the results table and graph. When apparent half-life (T1/2) is described for
any curve segment, it was calculated by the formula: T1/2 = 0.693/kel, where kel = - slope of the
ln(concentration) vs time curve. Non-compartmental modeling and initial compartmental modeling was
done using Phoenix WinNonLin 6.4, build 8 (Certara L.P., Princeton, NJ). Since WinNonLin lacks a built-in
3-compartment model with first-order absorption, final compartmental modeling was performed with
SimBiology tools in MATLAB software (MathWorks, Natwock, MA). Output PK parameter estimates are
considered to represent “apparent” rather than physiologic values.
Summary of all trials: Four separate IM ELQ-331 treatment trials were ultimately performed, the
rationale for which is described (see Results, below). For reference, Table 2 summarizes the various
trials to be discussed. Female Swiss-Webster mice (CFW, Charles River Laboratories. Inc. Raleigh, NC)
were used for Trials 1-3, and female CF-1 mice (Charles River Laboratories. Inc. Raleigh, NC) were used in
Trial 4. On arrival, the animals were acclimated for at least 7 days in quarantine. The animals were
housed in a cage maintained in a room with a temperature range of 64−79 °F, 34−68% relative humidity
and a 12-h light/dark cycle. Food and water were provided ad libitum during quarantine and throughout
the study. The animals were fed a standard rodent maintenance diet. The study design did not include a
formal drug toxicity assessment, however, blood sampling afforded frequent opportunities for
observation of the mice in addition to the standard, ongoing monitoring of animal welfare per protocols.
Transient or ongoing abnormalities in animal behavior or health, atypical of the normal course of events
during healthy animal housing, were required to be reported; none were noted.
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Table 2 title: Summary of the four treatment trials described in this report

Trial

Dose, prodrug

1

30 mg/kg ELQ-331
30 mg/kg ELQ-499
30 mg/kg ELQ-500

2

30 mg/kg ELQ-331

3

4

10 mg/kg ELQ-331
10 mg/kg ELQ-494
10 mg/kg ELQ-495
10 mg/kg ELQ-501
2.5 mg/kg ELQ-331
5 mg/kg ELQ-331
10 mg/kg ELQ-331

Time from dosing to testing
Blood stage
Plasma [ELQ-300] determination
challenge
47, 60, 90, 120 days
6, 12, 18, 24, 36, 48, 72 hours;
weekly 1-10, 14, 18, 22, 24 weeks
30, 70, 77 days
30, 70 days
30, 70 days
30, 83 days

Sporozoite
challenge

7, 14, 21, 40 days

137 days

n/a

48 days
77 days

n/a

n/a
n/a

14, 27 days

n/a

29 days

Results
Pilot testing for activity against blood stage infection and initial ELQ-300 snapshot PK: In Trial 1 (see
Figure 1), mice were injected with 30 mg/kg of ELQ-331, ELQ-499, or ELQ-500 on Day 0; controls
received no drug. To establish initial duration-of-effect parameters to guide subsequent studies, control
mice and mice from each treatment group were challenged with P. yoeliiK -infected erythrocytes on Day
7, 14, 21, or 40 after treatment, using a new sub-group of mice (N=3-4) at each timepoint. Blood smears
of all control mice, at all timepoints, showed patent infection after 5 days (mean parasitemia = 24 ±
4.9%). All treated mice remained parasite-free for at least 28 days.
Since these efficacy results indicated the persistence of elevated blood ELQ-300 concentration ([ELQ300]), we sought to quantify [ELQ-300] and compare values in the three prodrug treatment groups. Tail
vein blood samples were obtained 47, 60, 90, and 120 days after treatment (see Figure 1, table insert).
ELQ-331 produced a more sustained elevation of [ELQ-300] than the other tested prodrugs, remaining
above 100 nM for 4 months. ELQ-331 was therefore selected for Trial 2, a more detailed PK evaluation
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(see Pharmacokinetics of 30 mg/kg ELQ-331, below), and the still-persistent elevation of [ELQ-300]
prompted us to initiate sporozoite challenge testing in the remaining Trial 1 mice (see Causal
prophylactic efficacy, below).
Pharmacokinetics of 30 mg/kg IM ELQ-331 in sesame oil: In Trial 2, 24 mice were injected
intramuscularly with 30 mg/kg ELQ-331 and then divided into 6 groups. Blood samples were obtained
from one group at each timepoint in a repeating, sequential rotation, so that the same mice were
sampled at every sixth timepoint. Samples were taken 6, 12, 18, 24, 36, 48, and 72 hours after injection,
then weekly from 1 to 10 weeks, then every 4 weeks until 22 weeks, and a final sample was taken 24
weeks after dosing. Plasma [ELQ-331] and [ELQ-300] were measured at each time point (see Figure 2).
The lower limit of quantitation for [ELQ-331] was 1.2 nM, and values were below that cut-off or nondetectable in 86% of samples, even in the first days after treatment (see Figure 2, Inset 1). When
quantifiable, [ELQ-331] levels were trivial (mean = 4 nM, max = 11.5 nM), never reaching 1% of the
corresponding [ELQ-300]. Importantly, this indicates rapid and highly-efficient metabolism to ELQ-300.
Variability is evident in [ELQ-300] values at several time points within the first few days (see Figure 2,
Inset 1). Remembering that each of the first 6 time points represents a different group of mice, we
speculate that time points with very little variability (e.g., 24 and 36 hours) may represent consistent IM
delivery to all mice in that group, whereas high variability within a group may indicate that the portion
of the dose successfully deposited and retained within the muscle varied between mice. If true, then
early time points with lower and more consistent values may provide a more accurate picture of early
PK values after IM injection. Some of the highest early [ELQ-300] values may then represent the effect of
a portion of the dose being deposited or extruded outside the muscle to a site where rapid access to the
circulation can occur. Given the very small blood volume of a mouse, even a small fraction of the
injected dose rapidly reaching the circulation could produce transient high µM [ELQ-300], so it is difficult
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to judge whether or not the early variability actually reflects any substantial variation in the proportion
of the dose deposited intramuscularly. Our interpretation of [ELQ-300] values determined at later time
points (see below) is that the early variability here does not indicate substantial loss of the dose from
the injection site, and that successful dosing was broadly consistent. Since the objective is to rapidly
reach effective but sub-toxic concentrations, it is notable that at every early timepoint, [ELQ-300] is well
above 100 nM and does not approach concentrations associated with toxicity established in prior
studies in rats (see Discussion). With the above caveat in mind, i.e., that several early observed
timepoints may not be predictive of true IM PK, the ELQ-300 apparent Cmax was 3752 ± 582 nM, at Tmax =
18 hours.
The remaining concentration vs. time curve can be divided into 3 apparent phases. Between
approximately 1 week and 1 month after injection, despite the early variability discussed above, groups
show remarkably little variability and follow a consistent down-sloping curve with an apparent T1/2 = 14
days, far longer than the elimination T1/2 seen after intravenous dosing in mice (15 hours) (17). The long
apparent T1/2 during this phase is a strong indication that absorption of ELQ-300 from the injection site
into blood is ongoing. More speculatively, the consistency of PK results between and within groups
during this phase also suggests that, despite the wide variability seen earlier in the same mice, a high
proportion of the dose was consistently deposited intramuscularly. The next phase of the curve shows a
decrease in the slope of the concentration vs time curve, which remains relatively flat between 1 and 3
months after injection. Inserting [ELQ-300] values from Trial 1 reveals remarkable overlap (see Figure 2,
Inset 2) supporting the validity of the results. After day 90, the downward slope increases for the final
phase of the curve with an apparent terminal T1/2 = 29.5 days.
A full discussion of the PK modeling analysis (dataset definition, models comparison, model diagram,
expressions and equation) is presented in Additional File 3, the results of which will inform future
analysis and simulations. The main finding relevant to the consideration of ELQ-331 as a prototype for
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LAI-C is the qualitative finding of a multi-compartment PK profile for ELQ-300, including a large-capacity,
slow-exchange tissue compartment with significant impact on the duration of ELQ-300 exposure. This is
demonstrated in Figure 3, showing the curve, parameter estimates, and analysis of fit resulting from
fitting the “Edited” dataset using a 2-compartment model with first-order absorption and elimination
(For dataset definition, model diagram, expressions and equation, see Additional File 3). Results confirm
an excellent fit, with little difference between observed and predicted [ELQ-300] values, and evenly
distributed residuals. Since the slope of the [ELQ-300] vs. time curve after 30 days cannot be attributed
to either substantial ongoing absorption of ELQ-300 from the injection site (24, 25) or slow intrinsic
elimination of ELQ-300 (17), it must be predominantly related to release from the large-capacity
(Peripheralvol = 4.89 L vs. Centralvol = 0.12 L), slow-exchange (intercompartmental clearance [Q12] =
0.075 L/h) compartment.
Causal prophylactic efficacy of ELQ-331 after sporozoite challenge, corresponding plasma [ELQ-300], and
estimation of MECLAI-C: Mice treated with 30 mg/kg ELQ-331 from Trial 1 (137 days after treatment, N=3)
and Trial 2 (48 days after treatment, N=4), and untreated controls (N=2) were included in initial Py-GFPluc sporozoite challenge testing (see Table 3, upper segment). None of the treated mice developed
infection; controls had both liver stage and subsequent blood stage infection evident by luminescence
imaging. The finding that a protective [ELQ-300] was sustained for more than 4 months led us to initiate
Trial 3, evaluating a lower dose (10 mg/kg) of ELQ-331 in a limited comparison with three additional
ELQ-300 prodrugs.
In Trial 3, snapshot PK determinations 30 and 70 days after injection of 10 mg/kg showed that sustained
[ELQ-300] exposure was greater after ELQ-331 than after injection with long-chain variants ELQ-494 or
ELQ-495 (see Figure 4, table insert). ELQ-331 thus remained our lead, and sporozoite challenge to these
mice was done 77 days after injection (see Table 3, middle segment). Whole-body imaging of the mice
treated with 10 mg/kg ELQ-331, showed no evident liver stage infection, and a faint signal indicating
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blood stage infection in 1 of 4 animals. Liver stage infection was evident in only 3 of 4 control mice but
blood stage infection subsequently occurred in all 4, illustrating that the sensitivity of imaging is not
100%. Although whole-body luminescence imaging is our primary tool and a priori measure to
determine outcome after sporozoite challenge, we sought to gain added sensitivity by examining blood
smears of the four ELQ-331-treated mice immediately after imaging. Parasitemia was <0.1% in the
mouse that was faintly-positive by imaging, <0.01% in 2 mice, and one mouse was parasite-free. On the
day of imaging, [ELQ-300] values measured in these mice were 92, 75, 66, and 37 nM, suggesting 80 nM
as an initial estimate of MECLAI-C.
Table 3 title: Summary of 3 trials to assess causal prophylactic efficacy of ELQ-331 and other prodrugs
Luminescence imaging results

Closest
corresponding
[ELQ-300], nM
(time, mean±SEM,
individual values)

Treatment
group

Time from
treatment to
sporozoite
challenge

Controls

n/a

0/2 (0%)

n/a

ELQ-331, 30
mg/kg (Trial 1)

137 d

3/3 (100%)

120 d, 104.9±15.2,
134, 92, 88

ELQ-499

137 d

2/3 (67%)

120 d, 72.4±13,
98, 62, 57

ELQ-500

137 d

1/4 (25%)

120 d, 65.5±40,
185, 37, 22, 18

ELQ-331, 30
mg/kg (Trial 2)

48 d

4/4 (100%)

49 d, 213.7±25.4,
270, 229, 208, 148

Controls

n/a

0/4 (0%)

n/a

77 d

3/4 (75%)*
1/4 (25%) by
microscopy

77 d, 67.5±11.4,
92, 75, 66, 37

ELQ-331, 10
mg/kg

Liver stage
(2 days after
challenge)

Blood stage
(5-6 days after
challenge)

Mice
protected
from infection
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Controls

n/a

0/4 (0%)

n/a

27 d,
4/4 (100%)
29 d
4/4 (100%) by
95.8±3.7,
microscopy
104, 100, 90, 89
27 d,
4/4 (100%)*
ELQ-331, 5
29 d
2/4 (50%) by
50.3±5.7,
mg/kg
microscopy
61, 58, 46, 36
* Whole animal imaging was the a priori measure of efficacy, however, blood smear revealed occult
infection – see text
ELQ-331, 10
mg/kg

Table 3 legend: The upper table segment compares 30 mg/kg prodrug doses; the middle segment, 10
mg/kg prodrug doses; and the lower segment compares 2.5, 5, and 10 mg/kg ELQ-331 doses. Results
show more durable protection with ELQ-331 (30 mg/kg, >4 months; 10 mg/kg, >3 months) than other
tested prodrugs, and MECLAI-C between 60-80 nM (see text)
To begin to assess the relationship between dose and [ELQ-300] within the first month after ELQ-331
treatment, and to further explore the MECLAI-C, Trial 4 was initiated to compare 10, 5, and 2.5 mg/kg
doses of ELQ-331, with 8 mice in each treatment and control group. Snapshot [ELQ-300] determinations
14 days after dosing in mice from each treatment group (N=4) revealed plasma [ELQ-300] values of
183±29, 89±10, and 41±7 nM, respectively (see Figure 5, table insert). Measurement of [ELQ-300] was
repeated 27 days after dosing in the other 4 mice from each group and, excepting the 2.5 mg/kg group
with earlier sub-effective [ELQ-300], these same mice then underwent sporozoite challenge two days
later (see Table 3, lower segment). Mice treated with either 5 or 10 mg/kg of ELQ-331 showed no liver
or blood stage infection evident by imaging 2 or 5 days after inoculation, whereas all controls were
positive at both timepoints. Blood smears from the mice in the 5 and 10 mg/kg groups were made 7
days after sporozoite challenge to rule out low-grade infection below the level of detection by imaging.
No parasites were found among the mice treated with 10 mg/kg or in two of the mice treated with 5
mg/kg, but smears revealed 1% parasitemia in the other two animals. Weekly blood smears remained
parasite-free for 28 additional days in the uninfected mice. In the 5 mg/kg treatment group [ELQ-300]
values were 61, 58, 46, and 36nM, suggesting that in this trial, an estimate of 60 nM might be
appropriate for the MECLAI-C.
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This value is substantially lower than the 80 nM value described above, and the source of this difference
is unclear, but we suspect that it may be the result of differences in the effective inoculum. In the latter
experiment, there was a much weaker liver stage infection signal in control mice, suggesting that the
actual delivered inoculum of viable sporozoites was smaller, possibly the result of differences in salivary
gland transport time and sample processing. The latter experiment also used CF-1 mice, while the mice
in earlier trials were CFW (CF-1 mice were temporarily unavailable from the supplier), although this
seems unlikely to account for either reduced infectivity of the Py-GFP-luc sporozoites, or enhanced
potency of ELQ-300. Since it is unclear how experimental Py-GFP-luc inoculum size relates to predicting
efficacy against natural infection in humans, it seems prudent to consider 80 nM as a conservative target
MECLAI-C for LAI-C studies using the Py-GFP-luc sporozoite model in mice.
We did not design trials to assess MEC separately for causal and suppressive prophylaxis, but we believe
these MECLAI-C values to reflect true causal prophylaxis, and not suppression of early blood stage
infection. Per protocol, mice with any evident infection after sporozoite challenge were euthanized, so
the only opportunity to assess possible suppressive efficacy was in the mice with normal imaging results
and no parasites on initial blood smear. As noted above, 2 of those mice developed approximately 1%
parasitemia within 2 days, a rapid growth rate suggesting that [ELQ-300] was well below the effective
threshold against blood stage infection. Mice with only slightly higher [ELQ-300] were completely
protected, making it more likely that these values approached the threshold for causal prophylactic
efficacy instead. This is consistent with study findings after IM atovaquone, in which concentrations that
protected against sporozoites failed to protect against blood stage challenge (7).
Discussion
These results show that a single IM injection of 30 mg/kg ELQ-331 provides more than 4 months of
causal prophylaxis against malaria in mice and has a distinctive PK profile which contributes to its
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durable efficacy. These results were achieved using unaltered ELQ-331 dissolved in sesame oil and 1.2%
benzyl alcohol (as a preservative), without either vehicle optimization or formulation engineering,
suggesting that further enhancements are likely possible. Translation of these results to predictions of
efficacy in humans is speculative, but standard allometric scaling (26) provides reason for optimism. If
the in vivo ELQ-300 MECLAI against species causing malaria in humans is similar to that determined in
mice, allometric scaling would predict that the duration of effect of a given ELQ-331 dose would be
several-fold longer in humans than in mice, or, conversely, that a far lower dose would provide the same
duration of effect. Taken together, these observations suggest a very high likelihood that ELQ-331 can
feasibly provide the 3 months of protection currently called for in the MMV’s TPP for LAI-C against
malaria.
These results are also impressive in comparison to the scant available results from other drugs tested for
LAI-C. In two studies of engineered drug particles injected IM, mice were protected against P. berghei
sporozoite challenge for 56 days by a microsuspension of decoquinate (120 mg/kg) in peanut oil (8), and
for 28 days by atovaquone nanoparticles (200 mg/kg) (7). In unpublished studies of IM prodrugs of
atovaquone and ELQ-300, apparent MECLAI-c values for atovaquone and ELQ-300 were established based
on protection against sporozoite challenge 14 days after injection, and duration of efficacy was then
predicted based on how long the MECLAI-C was exceeded (Presentation by Chatterjee, A.K., TCP4: Intramuscular injections for malaria chemoprotection, in Symposium: What kind of molecules are needed to
control and eradicate malaria? ASTMH 66th Annual Meeting. 2017: Baltimore, MD). No later sporozoite
challenges were reported, but after 30 mg/kg injections, MECLAI-C was exceeded for more than 13 weeks
in dogs after the ELQ-300 prodrug (mCBK069), and in rats after the ATV prodrug (mCBK068). Given
allometric scaling predictions (clearance in mice < rats << dogs), the ELQ-331 performance
demonstrated here appears to surpass that of other agents for which reports are available.
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Although sesame oil is used as a vehicle for other LAI drugs, such as haloperidol (5), it is unlikely to
match the initial specifications set out by the MMV. The TPP for antimalarial LAI-C calls for a small
volume injection, ideally 1 mL or less in adults (< 2 mL is acceptable) and 0.5 mL or less in infants, and
that it be injectable through a 27-gauge needle (9). We find ELQ-331 in refined sesame oil to be soluble
to 83 mg/mL (see Additional File 2). Given that 30 mg/kg of ELQ-331 yields 4-5 months of protection in
mice, and allometric scaling would suggest 2.5 mg/kg as an equivalent dose in humans, it may or may
not prove difficult to deliver the dose needed for 3 months of protection for a large adult in 1 mL. Due to
viscosity, delivery through a very fine needle is problematic for any conventional oil. Oily vehicles
enhance the solubility of lipophilic drugs such as ELQ-331 and serve to slow release from the injection
site, and it is unclear how difficult it will be to achieve success with a low viscosity vehicle. ELQ-331 is
soluble in some low viscosity vehicles, such as Miglyol 840 (see Additonal File 2), and the results of
solubility testing in several vehicles provide a starting point for optimization. This suggests that
adequate solubility will be achievable, but it will also be necessary for the vehicle to have a desirable
drug release profile, local and systemic tolerability, and to be approved for injection use. Viscosity,
surface area, and composition of the vehicle all impact the time course of drug release from the
injection site (24), so substantial testing may be needed to find the ideal formulation.
Given the many advances in dosing formulation technology, there is little doubt that an ideal vehicle is
possible, but for large-scale use in malaria-endemic regions it will be essential to keep costs low and
avoid complex vehicle formulations, if possible. If finding an ideal, cost-effective vehicle formulation
proves difficult, then it is worth discussing whether inexpensive oil vehicles, such as sesame oil, deserve
consideration for LAI-C dosing. Certainly, use of the smallest bore needles will not be possible with oils,
but that is a lesser concern. Although the least possible injection discomfort is always desirable,
immunizations are routinely injected in infants via 23-25 g needles, so if it were ultimately not possible
to use a 27 g needle that would likely still be acceptable. Another concern expressed with regard to
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sesame oil is allergy risk, but it is uncertain whether such a risk actually exists. There are clearly cases of
eosinophilic pneumonitis after repeated daily injections of sesame oil (27), but this results from delayed
hypersensitivity to significant amounts of absorbed oil and not immediate hypersensitivity-mediated
acute allergic reaction. The antigens in sesame oil capable of causing dangerous acute allergic reactions
are present in crude sesame oil, but not in oil refined for pharmaceutical use and most injectable
pharmaceutical products in sesame oil do not include allergy risk as a contraindication or potential
adverse effect in product information (28). We were unable to find any documented cases in the
literature of dangerous acute allergic reaction to pharmaceutical sesame oil, and would argue that it
should not be ruled out on the basis of allergy risk. Beyond conventional IM injection, LAI-C is also an
excellent candidate application for other delivery systems such as subcutaneous implant (29) and in situ
gelling (30) technologies, providing numerous additional options for solubilization and delivery.
To account for the sustained efficacy of ELQ-331, it is useful to first consider its resulting overall [ELQ300] PK profile. During the initial downslope phase (days 7-35), absorption from the injection site,
distribution to and from tissue compartments, and elimination are likely occurring. ELQ-300 is highly
metabolically stable, so it is presumed that simple first order processes lead to elimination in feces and
urine, driven by mass action, and as a result, ELQ-300 elimination should follow a consistent,
concentration-dependent curve. Therefore, the inflection to a decreased slope of the curve (days 45-90)
must result from some combination of continued drug absorption, decreased distribution from blood to
tissue, and increased reabsorption from tissue to blood. While some drug absorption could still be
occurring at that time, for it to be the predominant cause of this plateau phase would require that fairly
constant and substantial absorption be ongoing for 3 months or more; this is inconsistent with studies of
the persistence of oil and drug at intramuscular injection sites in mice (25). Consistent with our
compartmental PK modeling, it is more likely that redistribution from other tissue compartments to
blood is predominant over the flat portion of the curve, and that the subsequent increased curve slope,
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evident after 90 days, results as redistribution from tissue decreases and elimination becomes gradually
more predominant. This final apparent change in slope is not accounted for in our standard
compartmental modeling equations, and it will be interesting to see in future studies if it is a
reproducible PK feature or merely an artifact due to our sampling protocol.
A full, accurate, and predictive model of IM ELQ-331 pharmacokinetics will be complex since it must
include the rate of release of ELQ-331 from the injected oil depot; conversion to ELQ-300 by esterases at
the injection site, in lymph, blood, and in liver and other organs; absorption into blood; extensive
protein binding in blood; distribution from blood to tissue; redistribution from tissue to blood; and
elimination, with each component involving its own set of numerous variables (24, 31). As a result, the
absolute values of parameters estimated from our simple compartmental PK analyses are unlikely to
represent physiologic values in vivo, but the findings are powerful, nonetheless. Fundamentally
important is the demonstration that prolonged redistribution of ELQ-300 from tissue sites is critical to
the sustained elevation of [ELQ-300] seen here. While the slow release of highly-lipophilic ELQ-331 from
oil and the long-elimination T1/2 of ELQ-300 certainly contribute to a long duration of effect, these are
properties shared by other antimalarials, whereas the capacity of a large, slow-exchange tissue
compartment to impact blood drug concentration and efficacy months after dosing is highly unusual,
and distinguishes ELQ-300 prodrugs such as ELQ-331 from other candidates reported thus far.
If the ideal PK profile for LAI-C is to rapidly achieve and maintain effective but non-toxic concentrations
of the active drug, in most cases this would be achieved by balancing elimination with sustained and
controlled release from the injection site throughout the period of risk. For medications delivered by
LAI, drug concentrations are typically most dependent on controlled and sustained release from the site
of delivery, optimized by choice of vehicle, vehicle mixtures, benzyl alcohol or other excipient content,
drug particle engineering, or other injection parameters (24, 29). This is evident in unpublished data
regarding atovaquone prodrugs (32), in which day 30 [atovaquone] values are highly dependent on
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formulation. In contrast, our results suggest that maintaining sustained and effective ELQ-300
concentrations after IM ELQ-331 is most closely related to loading and gradual unloading of ELQ-300, to
and from a repository tissue depot. While the pattern of ELQ-331 release from the injection site is
undoubtedly important in this process, controlled release apparently does not need to be sustained to
sustain durable protection because of the effect of the secondary depot. Because this PK profile is a
distinguishing feature of ELQ-331, it is important to consider its possible disadvantages and advantages
in the setting of LAI-C.
It will be important to identify the tissues and organs comprising this large-capacity, slow exchange
compartment to understand its impact on dosing considerations. If distribution is highly concentrated in
specific organs (e.g., liver), between-subject variability on the basis body mass index (BMI) obesity
would be less likely, whereas variations in BMI might lead to unwanted variations in response if
distribution is predominantly to general adipose tissue. Further study will allow development of the
physiology-based PK models needed to address these questions.
Extensive and sustained tissue stores of ELQ-300 could, theoretically, also prevent rapid termination of
exposure in case of toxicity, particularly if the site of toxicity were an organ in which the drug is highly
concentrated. After typical IM injection, this risk would be similar for any drug, but since removable drug
delivery systems (e.g., implants, removable gels) are a consideration for LAI-C as a safeguard against
toxicity, in that context a rich deposit of tissue-bound drug would be a comparative disadvantage. At this
time, there are no known safety concerns with ELQ-331, but with large required drug payloads,
sustained drug exposure, and planned use in remote settings with little safety surveillance capacity, the
safety of any drug used for LAI-C must be viewed skeptically.
During oral toxicity testing of ELQ-331, rats received a single dose of 15, 30, 100, 300, or 1000 mg/kg, or
7 daily doses of 5, 50, or 300 mg/kg (see Additional File 1). The lowest single dose with any evident
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toxicity was 300 mg/kg, which resulted in an ELQ-300 Cmax = 65-79 µM, and after lower doses,
concentrations well above 27-44 µM caused no apparent adverse effect. Seven daily doses of 5 mg/kg
(35 mg/kg cumulative) were tolerated without evidence of toxicity; [ELQ-300] values after the last dose
showed Cmax = 13-17 µM , and indicated that supra-µM concentrations had been maintained throughout
the week. While neither single nor 7 day dosing mirrors exposure after LAI-C, the very high [ELQ-300]
values associated with toxicity and the absence of toxicity after either a single 100 mg/kg or cumulative
35 mg/kg over 7 days are reassuring that the 4-month duration of protection reported here was
achieved safely (Cmax = < 5 µM).
If safety is ultimately established, then the ELQ-331 PK profile could be highly advantageous. By
exploiting intrinsic PK properties to maintain effective ELQ-300 concentrations, a shorter period of
tightly-controlled release might be needed, lessening the requirement for extensive formulation
engineering. In fact, if “loading” this compartment is sufficient to sustain concentrations, then this might
be achievable by many drug delivery routes, including short-term repeated oral dosing. Essentially, this
property adds another basis for extended efficacy, regardless of dosing strategy, and suggests that
duration of effect for far longer than 3 months may be more easily achievable with ELQ-300 prodrugs
than with atovaquone derivatives or other candidates.
This is advantageous beyond simply meeting the initial 3-month duration-of-effect target. To avoid
conditions favorable to generation of drug resistance during proposed combination therapy, it is
important that partner drugs are matched such that neither component falls below the MECLAI during
the period of risk. Achieving such a match is challenging, particularly if both components require
significant engineering to meet duration-of-effect requirements. If ELQ-331 requires little or no
engineering to achieve adequate extended activity, then adjusting duration of effect to match any
partner drug should be simplified, perhaps only requiring dose adjustment. Alternatively, in settings
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with a defined finite period of exposure risk, ELQ-331 might facilitate an acceptable PK mismatch in
which the effectiveness of a partner drug extends to the end of the risk period, but ELQ-331 effect
continues beyond that time. Finally, more reliable sustained efficacy may support consideration of ELQ331 for use without a partner.
Avoidance of monotherapy is based on the concern that a large number of parasites in the presence of
sub-effective drug concentrations promotes the generation or selection of resistant parasites. Clearly a
risk during blood stage infection, the same risk is theoretically possible during late liver stage infection
when infected hepatocytes house many thousands of developing merozoites. In contrast, an effective
causal prophylactic that prevents liver schizont development and survival faces less than a hundred nonreplicating parasites, making the risk of resistance generation exceedingly low if not zero. In the absence
of pre-existing resistance, monotherapy LAI-C is thus a logical consideration if an effective drug
concentration can safely and reliably be maintained beyond the end of exposure risk. This argument
applies only to true causal prophylaxis, so it is important to distinguish whether efficacy is solely on that
basis, or whether results are confounded by suppression of blood stage growth. ELQ-300 retains in vitro
potency against P. falciparum clinical isolates resistant to quinolines, anti-folates, artemisinin, and
atovaquone, among others, with no evidence of existing resistance. Generation of ELQ-300 resistance in
vitro is several orders of magnitude more difficult than with atovaquone, and like the case of
atovaquone, there is evidence of diminished transmissibility of ELQ-300 resistant parasites (personal
communication, G. McFadden). Given its multistage efficacy, potency, PK profile, and activity against
multidrug resistant parasites, ELQ-331 seems an ideal candidate for consideration of study as singledrug LAI-C, in addition to its less controversial proposed role in 2-component LAI-C.
To meet shelf-life requirements for LAI-C, ELQ-331 would need to undergo full stability testing in
whichever formulation is ultimately selected for LAI-C, but existing results are encouraging. Testing for 3
months at 40° C and 75% humidity showed ELQ-331 in a spray-dried dispersion formulation to be stable
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(manuscript submitted), and while no long-term testing has been done, it is stable in the short-term
after heating in sesame oil. Regarding the affordability of ELQ-331 as a component of LAI-C, there are no
obstacles to scalable, feasible, and cost-acceptable ELQ-331 synthesis, and only the need for an
unexpectedly complex and expensive final formulation could raise costs to a concerning level.
The above findings suggest that ELQ-331 is an excellent candidate for use in LAI-C against malaria and,
that among current tier 2 candidates, its characteristics are distinctly and perhaps uniquely suited to
that purpose, making it an appropriate prototype for study and comparison. Further studies are
warranted, including expanded toxicology studies of ELQ-331 relevant to LAI-C, consideration of
appropriate partner drugs, study of factors relevant to the consideration of monotherapy, exploration of
other vehicle formulations for IM injection, study of other delivery systems (e.g., implant, in situ gelling
polymer, oral), and continued comparison with other prodrugs.
Summary
A single IM injection of ELQ-331 in sesame oil in mice provided causal malaria prophylaxis for more than
4 months. Given allometric scaling predictions and available engineering and formulation technologies,
these results clearly support the feasibility of ELQ-331 to achieve duration of protection against malaria
for at least 3 months in humans. Furthermore, the distinct PK profile of ELQ-300 after ELQ-331
treatment may facilitate flexible delivery and formulation options and may also enable protection for far
longer than 3 months. Particularly in light of the favorable pharmacodynamic profile of ELQ-300, ELQ331 warrants consideration as a leading tier 2 prototype for LAI-C.
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Figure titles and legends
Figure 1 title: Summary of Trial 1 protocol and results
Figure 1 legend: The timepoints for blood stage challenges, blood sampling for snapshot
pharmacokinetic analysis, and sporozoite challenges are noted on the x-axis. The outcomes of efficacy
trials are represented graphically as red = no protection and green = complete protection, and the
proportion of challenged mice with each outcome is noted. The table insert summarizes the results of
snapshot PK at the indicated timepoints.
Figure 2 title: Pharmacokinetics of ELQ-300 after IM injection of 30 mg/kg ELQ-331 in Trial 2
Figure 2 legend: Main figure summarizes Trial 2 PK results in a log-linear plot of [ELQ-300] (mean ± SEM)
vs time. Inset 1 shows detail of days 0-7 in an expanded linear-linear plot of [ELQ-331] and [ELQ-300] vs
time. Inset 2 shows a composite log-linear plot combining values from Trial 1 and Trial 2.
Figure 3 title: Results of 2-compartment model fit
Figure 3 legend: (A) Linear-linear plot of observed mean [ELQ-300] values at each timepoint (+ symbols)
and values predicted from the curve fit (line). Estimated model parameters are shown in the insert
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table. Central = Apparent volume of the central compartment (L); Cl_Central = central compartment
clearance (L/hr); ka_Central = rate constant for absorption; Peripheral = apparent volume of the tissue
compartment; Q12 = intercompartmental clearance (L/hr). (B) Indicators of model fit validity:
correspondence of observed and predicted values, unbiased distribution of residuals.
Figure 4 title: Snapshot pharmacokinetics of ELQ-300 during Trial 3
Figure 4 legend: Snapshot plasma [ELQ-300] values from Trial 3, comparing IM injections of 10 mg/kg
ELQ-331 with two other ELQ-300 prodrugs. The log-linear graphical representation of [ELQ-300] vs. time
and summary table both display mean [ELQ-300] ± SEM.
Figure 5 title: Snapshot pharmacokinetics of ELQ-300 during Trial 4
Figure 5 legend: Snapshot plasma [ELQ-300] values from Trial 4, comparing IM injections of 2.5, 5, and
10 mg/kg ELQ-331. The log-linear graphical representation of [ELQ-300] vs. time and summary table
both display mean [ELQ-300] ± SEM.
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